Navigation Links
AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
Date:6/20/2012

-looking statements, including, but not limited to, statements related to AcelRx Pharmaceuticals' patent portfolio, including the useful life of the U.S. patent for a method of treating pain by administering a small-volume solid tablet containing sufentanil by adhering to the oral mucosa, the continued expansion of its patent protection, market exclusivity, its ability to protect its proprietary technology, the scope of patent protection, and issued and planned or anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, including the initiation of the third Phase 3 clinical studies for ARX-01, the timing of the top-line data from all three clinical trials, the timing of submission of an NDA with the FDA, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.    AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials; the success of its patent prosecution strategy; its ability to protect its proprietary technology, including the risks that pending patent applications may not result in issued patents; its ability to obtain sufficient financing to complete development and registration of its product candidates in the United States and Europe; its ability to obtain and maintain regulatory approvals of its product candidates; the market potential for its product candidates; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings, including its Annual Report on Form 10-K for the Year
'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Fish show autism-like gene expression in water with psychoactive pharmaceuticals
2. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
3. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
4. UCLAs Yi Tang receives Presidential Green Chemistry Challenge Award from EPA
5. Leading statistician receives national citation award
6. Dr. Karen Lloyd receives WHOIs Holger W. Jannasch Visiting Scholar Award
7. SF State biology department receives $1.5 million to support science teaching
8. SRI Sarnoffs Iris on the Move® N-Glance™ Identification System Receives Lenel Factory Certification
9. Washington University receives $8 million to lead international childhood malnutrition effort
10. UC Riverside receives grant for global health and development research
11. UC Riverside plant cell biologist receives top scientific honor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
(Date:3/31/2015)... 2015  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ... Software Defined Network Architecture (ET Software DNA® 2.0) platforms ... approximately $20.4 million for the year ended December 31, ... the year ended December 31, 2013. ... completed its multi-year transition away from its legacy landline ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... Measuring Energetics and Behaviour Using Accelerometry in Cane Toads ... Bufo marinus were introduced to Australia as a ... and damage new habitats they enter. Predictive models that can ... ground distribution could help to maximise control efficiency but to ...
... Cell biologist Daniel Gottschling, Ph.D., a member of the ... has been elected to membership in the American Academy ... nation,s oldest and most prestigious honorary societies and independent ... the molecular underpinnings of life clues that he ...
... NY, April 21, 2010 In recognition of Earth Day,s ... ) will provide complimentary online access to its journals ... Journal of Record; Environmental Justice; and Ecopsychology ... information about sustainability initiatives, the relationship between mankind and ...
Cached Biology News:Cane toad accelerometry and more 2Cane toad accelerometry and more 3Cane toad accelerometry and more 4Cane toad accelerometry and more 5Cane toad accelerometry and more 6Cell biologist Daniel Gottschling elected to American Academy of Arts & Sciences 2Expert commentary on Earth Day's 40th anniversary 2
(Date:5/5/2015)... May 5, 2015  Blueprint Medicines (NASDAQ: ... initial public offering of 9,367,708 shares of common ... per share, including shares of common stock issued ... their option to purchase additional shares. The gross ... Medicines were approximately $168.6 million, before underwriting discounts and ...
(Date:5/5/2015)... , May 5, 2015 Roka Bioscience, Inc. ... providing advanced testing solutions for the detection of foodborne pathogens, ... at the Bank of America Merrill Lynch 2015 Health Care ... be held at Encore at the Wynn, Las ... of the presentation will be available through the investor relations ...
(Date:5/5/2015)... Poway, CA (PRWEB) May 05, 2015 ... Pall Life Science Animal Health, Jeffrey Schaffer, DVM, ... , “With over 15 years of experience in ... be a great addition to our veterinarian lead ... Commercial Officer, explains. “Dr. Schaffer will be responsible ...
(Date:5/5/2015)... DUBLIN , May 05, 2015 /PRNewswire/ ... ) has announced the addition of the ... report to their offering. Macromolecules ... acids undergo separation or are broken into ... biotechnological products. This separation requires various advanced ...
Breaking Biology Technology:Blueprint Medicines Announces Closing of Initial Public Offering 2Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2
... Biosciences,Incorporated (Nasdaq: KOSN ) today announced that ... as Chief Executive Officer, effectively immediately.,Ms. Kim joined ... and Chief,Business Officer, and was appointed President in ... of the Board, commented: "We,believe that Helen possesses ...
... and,the president of one of the area,s major ... Committee as winners of the region,s third,bioscience award ... Region Bioscience Awards are:, -- Best New ... CEO, CSA,Medical, Inc. Askew,s very young Baltimore-based company ...
... Study Successfully Hit Primary End Point of ... Toward Superiority over the Market Leader, ... (NASDAQ: ANPI , TSX: ANP), a ... today that the clinical data from its ...
Cached Biology Technology:Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer 2Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer 3Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer 4Three CEOs and University President Named Winners of Greater Baltimore Committee's 2008 Baltimore Region Bioscience Awards 2960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 2960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 3960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 4960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 5960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 6960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 7
RABBIT ANTI ISOCITRATE DEHYDROGENASE...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
Recombinant Feline IL-2, CF...
... Fernandez and G. Butcher (1998). • The ... much research in the immunology area. There ... MHC proteins and in their function as ... faced with the prospect of tackling biochemical ...
Biology Products: